Aer Therapeutics is a clinical-stage biopharmaceutical company dedicated to delivering a therapeutic solution to patients suffering from muco-obstructive lung diseases. The company's initial focus is chronic obstructive pulmonary disease (COPD) with other muco-obstructive lung diseases to follow, including asthma, cystic fibrosis, primary ciliary dyskinesia, and non–cystic fibrosis bronchiectasis.